Enedra secures funding to advance AI-driven cancer platform
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
List view / Grid view
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
AI is reshaping drug discovery – but not without resistance. In this two-part conversation, André França and Eli Pollock share honest insights about the real barriers to AI adoption in life sciences and how embedding domain expertise into AI workflows might be the key to unlocking its full potential.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
Japanese researchers have developed a new enzyme technology that can precisely alter the levels of mutated mitochondrial DNA in patient-derived stem cells, offering a promising new approach for treating mitochondrial disorders.
The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases.
Huntington's disease remains a major challenge, but allele-selective gene editing offers new hope. By targeting only the mutant gene, this approach could provide a one-time, durable treatment. Life Edit’s Dr Amy Pooler reveals how this innovative therapy could reshape HD treatment.
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the most treatment-resistant cancers.
Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment.
A glycine-based compound developed at the University of Michigan, originally designed to treat severe fatty liver disease, has shown powerful effects in reducing atherosclerosis and vascular calcification in animal models.
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
Men and women heal bone injuries through distinct biological processes, challenging assumptions in regenerative medicine. The findings support the development of personalised implants and more effective, sex-specific treatment strategies.
New research reveals that the flexible ‘fuzzy coat’ surrounding α-synuclein fibrils plays a critical role in how Parkinson’s disease spreads between brain cells.
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
A specialised group of immune cells in the gut has been found to prevent allergic reactions - a discovery that could lead to new treatments for allergies and autoimmune diseases.